Huperzine-A to Help With Mental Problems and the Inability to Care for Onself in Patients With Schizophrenia
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01012830 |
Recruitment Status : Unknown
Verified November 2009 by VA Nebraska Western Iowa Health Care System.
Recruitment status was: Not yet recruiting
First Posted : November 13, 2009
Last Update Posted : November 13, 2009
|
- Study Details
- Tabular View
- Results Submitted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Schizophrenia Dementia | Drug: Huperzine A | Phase 4 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 15 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Huperzine-A for Cognitive Dysfunction and Functional Status in Schizophrenia |
Study Start Date : | December 2009 |
Estimated Primary Completion Date : | December 2010 |
Estimated Study Completion Date : | April 2011 |

Arm | Intervention/treatment |
---|---|
Experimental: Huperzine A
200 micrograms (mcg) of HuperzineA taken twice daily.
|
Drug: Huperzine A
Huperzine A in 200 microgram (mcg) capsules taken twice daily for 8 weeks.
Other Names:
|
- MATRICS Consensus Cognitive Battery [ Time Frame: First visit, 4 weeks, 8 weeks ]
- University of California Performance Skills Assessment-Brief (UPSA-B) [ Time Frame: First visit, 8 weeks ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 19 Years to 59 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- age 19-59
- diagnosis of schizophrenia by MINI
- cognition score 1 standard deviation below published norms in controls
- clinically stable for 12 weeks i.e. on the same antipsychotic(s) for 8 weeks and stable dose for at least 4 weeks
- have no more than moderate severity rating on hallucinations, delusions formal thought disorder (BPRS), negative symptoms (PANSS_N)
- minimal EPS (Simpson-Angus <6)
- minimal depression (Calgary <10)
- stable dose of other psychotropics (2 months)
- not pregnant.
Exclusion Criteria:
- history of active peptic ulcer disease within 1 year of screening
- clinically significant cardiac arrhythmia
- resting pulse less than 50
- active cancer (skin tumors other than melanoma are not excluded)
- history of clinically significant stroke
- current evidence or history in the past 2 years of epilepsy, focal brain lesion
- start of cholinesterase inhibitors/ cognitive enhancers (galantamine, rivastigmine, donepezil, vitamin E and memantine) within 2 months of screening, 8. use of medications with significant central nervous system anticholinergic activity within 2 months of screening.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01012830
Contact: Daniel A Ramirez, BS | 800-451-5796 ext 4036 | Daniel.Ramirez@va.gov |
United States, Nebraska | |
Veterans Affairs Nebraska Western Iowa Health Care System | |
Omaha, Nebraska, United States, 68105 | |
Contact: Daniel A Ramirez, BS 800-451-5796 ext 4036 Daniel.Ramirez@va.gov | |
Principal Investigator: Prasad R Padala, MD, MS |
Principal Investigator: | Prasad R Padala, MD, MS | VA Office of Research and Development |
Responsible Party: | Prasad R. Padala, M.D., VA Nebraska Western Iowa Health Care System |
ClinicalTrials.gov Identifier: | NCT01012830 |
Other Study ID Numbers: |
636-631 |
First Posted: | November 13, 2009 Key Record Dates |
Last Update Posted: | November 13, 2009 |
Last Verified: | November 2009 |
Schizophrenia Cognitive Disorders Dementia Huperzine A HupA |
Dementia Schizophrenia Schizophrenia Spectrum and Other Psychotic Disorders Mental Disorders Brain Diseases Central Nervous System Diseases Nervous System Diseases Neurocognitive Disorders Huperzine A |
Cholinesterase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Cholinergic Agents Neurotransmitter Agents Physiological Effects of Drugs Neuroprotective Agents Protective Agents |